Tetrahydrocannabinol inhibition of macrophage nitric oxide production

Biochemical Pharmacology

Volumn 52, Issue 5, 1996, Pages 743-751

  Coffey, Ronald G ^a   Yamamoto, Yoshimasa ^a   Snella, Elizabeth ^a   Pross, Susan ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

anandamide; cannabinoid; cyclic AMP; interferon ; lipopolysaccharide

Indexed keywords

11 HYDROXYTETRAHYDROCANNABINOL; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CYCLIC AMP; DELTA8 TETRAHYDROCANNABINOL; GAMMA INTERFERON; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FEMALE; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STEREOCHEMISTRY;

EID: 0030582449     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00356-5     Document Type: Article

References (47)

1. 1. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D and Schein PS, Efficacy of tetrahydrocannabinol in patients refractory to standard anticmetic therapy. Invest New Drugs 6: 243-246, 1988.
2. 2. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV and Wadleigh RG, Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40: 695-700, 1991.
3. 3. Kaminski NE, Mechanisms of immune modulation by cannabinoids. In: Immunotoxicology and Immunopharmacology (Eds. Dean JH, Luster MI, Munson AE and Kimber I), 2nd Edn, pp. 349-362. Raven Press, New York, 1994.
4. 4. Specter S, Lancz G, Westrich G and Friedman H, Delta-9-tetrahydrocannabinol augments murine retroviral induced immunosuppression and infection. Int J Immunopharmacol 13: 411-417, 1991.
5. 5. Blanchard DK, Newton C, Klein TW, Stewart WE II and Friedman H, In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int J Immunopharmacol 8: 819-824, 1986.
6. 6. Munson AE, Sanders VM, Bradley SG, Loveless SE and Harris LS, Lethal interaction of bacterial lipopolysaccharide and naturally occurring cannabinoids. J Reticuloendothel Soc 24: 647-655, 1978.
7. 7. Klein TW, Newton C, Widen R and Friedman H, Delta 9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J Pharmacol Exp Ther 267: 635-640, 1993.
8. 8. Pross S, Nakano Y, Smith J, Widen R, Rodriguez R, Newton C and Friedman H, Suppressive effect of tetrahydrocannabinol on specific T cell subpopulations in the thymus. Thymus 19: 97-104, 1992.
9. 9. Specter S, Rivenbark M, Newton C, Kawakami Y and Lancz G, Prevention and reversal of delta-9-tetrahydrocannabinol induced depression of natural killer cell activity by interleukin-2. Int J Immunopharmacol 11: 63-68, 1980.
10. 10. Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K and Cabral GA, Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15: 371-382, 1993.
11. 11. Tang JL, Lancz G, Specter S and Bullock H, Marijuana and immunity: Tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int J Immunopharmacol 14: 253-262, 1992.
12. 12. Lopez-Cepero M, Friedman M, Klein T and Friedman H, Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 39: 679-686, 1986.
13. 13. Specter S, Lancz G and Goodfellow D, Suppression of human macrophage function in vitro by delta-9-tetrahydrocannabinol. J Leukoc Biol 50: 423-426, 1991.
14. 14. Zheng ZM, Specter S and Friedman H, Inhibition by delta-9-tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and human macrophages. Int J Immunopharmacol 14: 1445-1452, 1992.
15. 15. Ding AH, Nathan CF and Stuehr DJ, Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141: 2407-2412, 1988.
16. 16. Moncada S, Palmer MJ and Higgs EA, Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
17. 17. Vandeloosdrecht AA, Beelen RHJ, Ossenkoppele GJ, Broekhoven MG and Langenhuijsen MMAC, A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174: 311-320, 1994.
18. 15N]nitrate in biological fluids. Anal Biochem 126: 131-138, 1982.
19. 19. Coffey RG, Davis JS and Djeu JY, Stimulation of guanylate cyclase activity and reduction of adenylate cyclase activity by granulocyte-macrophage colony-stimulating factor in human blood neutrophils. J lmmunol 146: 2695-2701, 1988.
20. 20. Yamamoto Y, Retzlaff C, He P, Klein TW and Friedman H, Quantitative reverse transcription-PCR analysis of Legionella pneumophila-induced cytokine mRNA in different macrophage populations by high-performance liquid chromatography. Clin Diagnostic Lab Immunol 2: 18-24, 1995.
21. 21. Ehlers S, Mielke MEA, Blankenstein T and Hahn H, Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes. J Immunol 149: 3016-3022, 1992.
22. 22. Nomura T, Ichinose H, Sumi-Ichinose C, Nomura H, Hagino Y, Fujita K and Nagatsu T, Cloning and sequencing of cDNA encoding mouse GTP cyclohydrolase I. Biochem Biophys Res Commun 191: 523-527, 1993.
23. 23. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
24. 24. Schmidt HHHW, Pollock JS, Nakane M, Gorsky LD, Forstermann U and Murad F, Purification of a soluble isoform of guanylyl cyclase-activating factor synthase. Proc Natl Acad Sci USA 88: 365-369, 1991.
25. 25. DeVane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaus A, Etinger A and Mechoulam R, Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
26. 26. Diaz S, Specter S and Coffey R, Suppression of lymphocyte adenosine 3′:5′-cyclic monophosphate (cAMP) by delta-9-tetrahydrocannabinol. Int J Immunopharmacol 15: 523-532, 1993.
27. 27. Felder CC, Veluz JS, Williams HL, Briley EM and Matsuda L, Cannabinoid agonists stimulate both receptor- and non-receptor mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 42: 838-845, 1992.
28. 28. Cabral GA and Fischer-Stenger K, Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. Life Sci 54: 1831-1844, 1994.
29. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29: 307-313, 1986.
30. 30. Kaminski NE, Abood ME, Kessler FK, Martin BR and Schatz AR, Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42: 736-742, 1992.
31. 31. Kaminski NE, Koh WS, Yang KH, Lee M and Kassier FK, Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48: 1899-1908, 1994.
32. 32. Imai T, Hirata Y, Kanno K and Marumo F, Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 93: 543-549, 1994.
33. 33. Gaillard T, Mulsch A, Busse R, Klein H and Decker K, Regulation of nitric oxide production by stimulated rat Kupffer cells. Pathobiology 59: 280-283, 1991.
34. 34. Sowa G and Przewlocki R, cAMP analogues and cholera toxin stimulate the accumulation of nitrite in rat peritoneal macrophage cultures. Eur J Pharmacol 266: 125-129, 1994.
35. 2 activity by cannabinoids in whole cells and subcellular preparations. J Clin Pharmacol 21: 240S-248S, 1981.
36. 36. Laychock SG, Hoffman JM, Meisel E and Bilgin S, Pancreatic islet arachidonic acid turnover and metabolism and insulin release in response to delta-9-tetrahydrocannabinol. Biochem Pharmacol 25: 2003-2008, 1986.
37. 37. Diaz S, Specter S, Vanderhoek JY and Coffey RG, The effect of delta-9 tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J Pharmacol Exp Ther 268: 1289-1296, 1994.
38. 38. Mechoulam R, Vogel Z and Barg J, CNS cannabinoid receptors - Role and therapeutic implications for CNS disorders. CNS Drugs 2: 255-260, 1994.
39. 39. Munro S, Thomas KL and Abushaar M, Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
40. 40. Nathan C, Nitric oxide as a secretory product of mammalian cells. FASEB J 6: 3051-3064, 1992.
41. 41. Efron DT, Kirk SJ, Regan MC, Wasserkrug HL and Barbul A, Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 110: 327-334, 1991.
42. 42. Coffey RG, Immune response, cyclic GMP and the arginine connection. In: Nitric Oxide, Brain, and the Immune System (Ed. Moncada S), pp. 75-84. Portland Press, Beckenham, England, 1994.
43. 43. Fu Y and Blankenhorn EP, Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J Immunol 148: 2217-2222, 1992.
44. 44. Kolb H and Kolb-Bachofen V, Nitric oxide: A pathogenetic factor in autoimmunity. Immunol Today 13: 157-160, 1992.
45. 45. MacMicking JD, Nathan C, Hom G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie Q-W, Sokol K, Hutchinson N, Chen H and Mudgett JS, Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81: 641-650, 1995.
46. 46. Wallace JM, Tashkin DP, Oishi JS and Barbers RG. Peripheral blood lymphocyte subpopulations and mitogen responsiveness. J Psychoactive Drugs 20: 9-14, 1988.
47. 47. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF and Wahl SM, Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178: 749-754, 1993.